drugset / Trial / NCT00836888
ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect and efficacy of ONO-4538.
Timeline
- Start
- 2009-01
- Primary completion
- 2010-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | Other |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Other |
| Subject | Nivolumab | Monoclonal antibody | 10 mg/kg | Other |
| Subject | Nivolumab | Monoclonal antibody | 20 mg/kg | Other |